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Background
Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host
disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be
effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data
were from small numbers of patients or retrospective analyses. We, therefore, conducted a mul-
ticenter phase II study to confirm the efficacy of this treatment strategy that targets B cells. 
Design and Methods
We diagnosed and evaluated chronic graft-versus-host disease according to the National
Institute of Health criteria for clinical trials on this condition. The treatment consisted of week-
ly intravenous infusions of rituximab for 4 weeks followed by monthly rituximab for 4 months.
We evaluated the patients’ responses and monitored their disease activity until their final visit,
which was on day 365. We also assessed the patients’ subsequent quality of life and serum lev-
els of B-cell-activating factor of the tumor necrosis factor family. 
Results
Among 37 patients enrolled (median age, 29 years; range 8-57 years), 32 patients responded to
rituximab with 8 complete and 24 partial responses. Twenty-one patients maintained their
response for 1 year, so their steroid treatment was discontinued or its dose reduced (21/37, or
56.8%), and their scores representing quality of life were improved although these changes
were not statistically significant. The responses were better for clinical manifestations of the
skin, oral cavity and musculoskeletal system  (response rate, 71.4-100%) than for other organs.
However, infectious complications and primary disease relapse accounted for the majority of
treatment failure. The pre-treatment serum level of B cell-activating factor of the tumor necrosis
factor family was not associated with better treatment outcome (P=0.147).
Conclusions
Rituximab could improve clinical responses and quality of life of patients with steroid-refrac-
tory chronic graft-versus-host disease, although such patients may need active prophylaxis
against infection. (ClinicalTrials.gov Identifier: #NCT00472225)
Key words: rituximab, chronic graft-versus-host disease, steroid, allogeneic stem cell transplan-
tation, quality of life.
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Introduction
Chronic graft-versus-host disease (GVHD) is a major
cause of morbidity and mortality in survivors of allogeneic
stem cell transplantation.1 Chronic GVHD has variable
clinical manifestations, similar to those in autoimmune
disorders, and may involve diverse tissues, including the
skin, eyes, oral mucosa, liver, lungs, and gut.2 Primary
treatment consists of steroids alone or in combination
with calcineurin inhibitors such as cyclosporine or
tacrolimus, extending for several months and often
years.3,4 Many patients do, however, respond poorly to
treatment, resulting in late mortality.4,5 Furthermore,
chronic GVHD and its prolonged treatment may seriously
impair a patient’s quality of life (QOL).6 There are few
treatments available and there is currently no consensus
on the best treatment for steroid-refractory chronic
GVHD. There is an urgent need for new options of effec-
tive therapy.
Although we do not fully understand the pathogenesis
of chronic GVHD, studies suggest that B cells, as well as
donor-derived T cells, may be involved. Thus, alloantibod-
ies to Y chromosome-associated minor histocompatibility
antigens correlate with chronic GVHD in sex-mismatched
allogeneic stem cell transplants, and donor-derived B cells
have been shown to be required to induce chronic GVHD
in a murine model.7,8 Elevated levels of B cell-activating
factor of the tumor necrosis factor family (BAFF) are also
correlated with the occurrence and severity of chronic
GVHD.9,10 Thus, B cells may present a therapeutic target in
the treatment of chronic GVHD, especially in steroid-
refractory cases. 
Rituximab is a chimeric monoclonal antibody that binds
to CD20 antigens on the surface of B cells. Although wide-
ly used to treat B-cell lymphomas, it has recently been
shown to be effective in steroid-refractory chronic GVHD;
a meta-analysis found a response rate of up to 70%.11
Most previous reports, however, concerned single cases or
retrospective analyses of small series of patients.12-15 All but
one of four prospective studies included only three to
seven patients.16-19 Furthermore, most previous studies
classified chronic GVHD as limited or extensive disease
according to a historical definition, and response criteria
varied among the studies. As a result, prospective and ret-
rospective studies have produced variable response rates
and organ-specific responses.11 To standardize the criteria
for the diagnosis of chronic GVHD and its response to
treatment, the National Institutes of Health (NIH)
Consensus Development Project released new criteria for
clinical trials in this disease.20,21 Up to now, only one small
prospective study of seven patients has used these NIH
criteria,19 and none has addressed patients’ QOL. We,
therefore, performed this phase II study to evaluate both
the effectiveness of rituximab (i.e., the clinical response)
and QOL in patients with steroid-refractory chronic
GVHD, based on the NIH criteria for clinical trials.20,21
Design and Methods
Study design 
This study was an open-label, multicenter, prospective, phase II
study to evaluate the efficacy of rituximab in terms of response to
treatment, changes in QOL and discontinuation of steroids.
Eligible subjects were patients with steroid-refractory chronic
GVHD who required treatment. Thus, all patients had at least one
diagnostic sign of chronic GVHD or at least one distinctive mani-
festation confirmed by biopsy or other laboratory tests according
to the criteria for clinical trials in chronic GVHD released by the
NIH Consensus Development Project.20 All patients also had at
least a moderate score for chronic GVHD, defined as a maximum
score of at least two in any affected organ or a score of one in all
affected organs in the global scoring system for chronic GVHD.20
Steroid-refractory chronic GVHD was defined as chronic GVHD
of sustained severity during the last full month during which the
patients had received the equivalent of prednisone 0.5 mg/kg or
more per day or 1 mg/kg or more every other day. Concomitant
use of other immunosuppressive agents was permitted except for
extracorporeal phototherapy or other experimental treatments.
We excluded patients who had received donor lymphocyte infu-
sions within 100 days preceding the trial. Patients who had a seri-
ous comorbid condition, such as an active infection, or a life
expectancy of less than 1 month were also not eligible to partici-
pate. The institutional review board at each participating center
approved this study, and all patients provided written informed
consent. This trial was registered at www.clinicaltrials.gov as
#NCT00472225.
Treatment and response evaluation
The treatment consisted of weekly intravenous infusions of rit-
uximab 375 mg/m2 for 4 weeks followed by monthly rituximab
for 4 months (Figure 1A). Baseline evaluations were performed
within 7 days before enrollment, and the first treatment response
was evaluated after completion of the weekly rituximab infusions
(day 29, Figure 1A). Four weeks later (day 57), we evaluated all
patients’ responses again, after which the patients were entered
into the maintenance phase, regardless of their response, except in
the case of a serious adverse event or refusal to receive further
treatment. We evaluated the responses during the maintenance
phase (days 85, 113, and 141), and monitored patients three times
before their final visit of the study period (day 365). At each visit,
routine blood tests, including complete blood cell counts and
serum biochemistry, and imaging studies, including chest X-rays,
were performed. Tests such as Schirmer’s test were used to evalu-
ate organ-specific responses. Patients could receive prophylaxis
with acyclovir and trimethoprim-sulfamethoxazole for viral and
fungal infections if this was decided to be appropriate by each
investigator on the basis  of each patient’s clinical context. 
Response definition and steroid tapering
We used the criteria from the NIH Consensus Development
Project to define a response.21 Complete response was defined as
the resolution of all signs and symptoms associated with chronic
GVHD. Partial response was defined as a clinical score reduction
of at least one point in one or more affected organs, with no evi-
dence of deterioration in any organ. Objective responses therefore
included both complete and partial responses. Progressive disease
was defined as a clinical score increase of at least one point in one
or more organs or occurrence of any new symptoms or signs of
chronic GVHD. We defined a lack of response without the
requirement for additional immunosuppressive therapy as no
response. Based on the objective response, investigators could
reduce the steroid dosage. Subjects with no response or progres-
sive disease received a fixed or increased dose of steroid until the
next response evaluation. Regimens for immunosuppressants
other than steroids were similarly modified. 
Quality of life measurement 
The Short Form-36 (SF-36) questionnaire, version 2.0
(QualityMetric, RI, USA), was used to evaluate QOL at baseline,
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on day 57, and on day 365. The eight domains explored by the SF-
36 are general health perceptions, physical function, general men-
tal health, role function limitation due to physical problems, role
function limitation due to emotional problems, bodily pain, vitali-
ty, and social function. These data were then used to compute
physical component summary and mental component summary
scores using the “SF-36 Physical and Mental Health Summary
Scales”.22 The score was normalized to that of healthy people, set
at 50 (±10). 
Sample collection and measurement of serum B-cell-
activating factor of the tumor necrosis factor family
Serum samples were obtained during the study period (at base-
line and on days 57 and 365) and were stored at –80 °C until tested
with an enzyme-linked immunosorbent assay (ELISA). To meas-
ure serum BAFF, samples were thawed and 50 μL were placed in
each of the wells of an ELISA plate coated with a mouse mono-
clonal antibody against human BAFF (Quantikine Human BAFF
Immunoassay®, R&D Systems, Minneapolis, MN, USA). The
ELISA was performed according to the manufacturer’s manual,
and the absorbance at 450 nm was measured. Serum BAFF
(pg/mL) was calculated from a standard curve produced with
40,000 pg/mL of recombinant human BAFF. To compare BAFF lev-
els with immune globulin (Ig) levels, serum IgG, IgA, and IgM
were measured in the same samples. 
Sample size calculation and statistical analysis
A previous study with weekly administration of rituximab
showed a 70% overall response rate in steroid-refractory chronic
GVHD.18 Thus, if our treatment regimen of weekly rituximab and
monthly rituximab maintenance failed to show more than a 50%
overall response, the treatment was to be deemed ineffective. A
response rate greater than 70%, however, could indicate effective-
ness in the treatment of steroid-refractory chronic GVHD. Based
on the above assumption, we designed this trial using Simon’s
minimax two-stage testing procedure.23 Assuming a target level of
interest, p1=0.70, and a lower activity level of p0=0.50, 23 patients
needed to be accrued; if 13 or more objective responses were
observed, the trial was to be continued to include 37 patients. This
design provided a probability of 0.05 or less of accepting a treat-
ment worse than p0 and a probability of 0.20 or less for rejecting
a treatment better than p1. 
We used the χ2 test to evaluate the relationships between the
responses to the clinical variables. Improvement in QOL was
determined by intent-to-treat (ITT) and per protocol (PP) analyses.
The ITT analysis set included the data of all patients with at least
one QOL measurement after treatment. Missing values in the ITT
set were imputed with the ‘last observations carried forward’
method. The PP analysis set included only the patients with com-
plete QOL observations. A two-sided P value of less than 0.05 was
considered to be statistically significant.
Results
Characteristics of patients and allogeneic stem cell
transplants
This study included 37 patients ranging in age from 8 to
57 years (median, 29 years) (Table 1). Approximately one-
third of these patients (32.4%) had a poor performance
status (ECOG grade 2/3) at the time of entry. Although we
excluded patients with serious co-morbidities, we includ-
ed those with diabetes mellitus and previous tuberculosis.
There were no patients with hepatitis B virus antigen,
antibody against hepatitis C virus, or human immunode-
ficiency virus. All patients underwent allogeneic stem cell
transplantation and two patients received a second allo-
geneic stem cell transplant. Myeloablative conditioning
was the dominant procedure (78.4%, Table 1), and cells
from unrelated donors were more commonly used than
cells from sibling donors. Bone marrow was the main
source of stem cells, and mismatches of ABO type and sex
occurred more frequently than did matched cases. 
Characteristics of steroid-refractory,
chronic graft-versus-host disease 
All patients had at least moderate chronic GVHD, with
a median duration of 5.2 months (range, 2.2-25.5 months)
(Table 1) before entry into the study. More than one-half
of patients had a previous history of acute GVHD
(56.8%). The disease involved diverse organs from skin to
gut (Table 1). Three patients had other immune-mediated
disorders; two had hemolytic anemia and one had pro-
teinuria (Table 1). The majority of patients had multiple-
organ involvement, with a median of 2.78 (range, 1-5)
organs per person. At the time of enrollment, all patients
received a steroid with or without other immunosuppres-
sive agents, and the median duration of steroid treatment
was 1.8 months (range, 1-28 months). 
Response and steroid discontinuation
We assessed response to treatment at designated time
points during the 1-year study period (Figure 1A). Some
patients maintained their initial response, while in others,
the initial response diminished during follow-up. In the
calculation of maximum response for the study period,
eight patients had a complete response and 24 patients
had a partial response (Table 2). The median time to max-
imal response was on day 29 (Figure 1B; range, day 0 to
day 252). Overall, 21 patients maintained their response
until the final visit. In these patients (21/37, or 56.8%) the
Rituximab for steroid-refractory chronic GVHD
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Figure 1. (A) Treatment
schedule and response
evaluation. (B) The time
to maximal response in
37 patients. The medi-
an time to maximal
response was day 29,
and the range was from
day 0 (for non-respon-
ders) to day 252.
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steroid treatment was then discontinued or its dose
reduced (Table 2). Because the median number of involved
organs was 2.78 (range, 1-5) organs per person, the num-
ber of evaluable organs was larger than the number of
patients. Evaluation of response according to the organs
involved showed that lesions in the musculoskeletal sys-
tem, skin and oral cavity responded better than those in
the eyes, liver and gut (Table 3). Only one patient showed
a partial response (9.1%, 1/11, Table 3) in the lung, the
organ least responsive to treatment. Immune-mediated
manifestations such as hemolytic anemia responded well
to rituximab (Table 3). The baseline characteristics of
patients, including duration of chronic GVHD, did not
influence the response to rituximab (P>0.05, data not
shown). However, all patients up to 15 years old (n=8) had
an objective response, and seven of these maintained their
responses. Specific features of the allogeneic stem cell
transplants, such as stem cell source, HLA matching, or the
type of conditioning, were not associated with response
(P>0.05, data not shown).
Mortality and drop-out
Five patients did not respond to treatment, so they
dropped out from the study (#18, 21, 24, 29, 32). Of these,
two patients (#29, 32) dropped out after day 29 because of
suspected pulmonary tuberculosis and infectious colitis,
respectively. Tests showed, however, that they did not
have those complications, and they both recovered.
Another patient (#18) with no response withdrew his con-
sent to continued treatment after day 85. The other two
patients (#21, 24) died of pneumonia (Table 2). On the
other hand, six patients showed disease progression after
they had achieved a partial response (#6, 9, 10, 13, 15, 36,
Table 2). Among these six patients, two patients (#6, 9)
died of pneumonia and sepsis during follow-up, and one
patient with lung involvement (bronchiolitis obliterans)
died of pulmonary hemorrhage (#36). Another patient
(#10) showed disease progression late in follow-up (day
252). The other two patients dropped out when their dis-
ease progressed (#13, 15). The hematologic toxicity asso-
ciated with the rituximab infusions was acceptable
because only one patient (#4) showed grade III neutrope-
nia on day 113. However, this patient died due to infection
after neutropenia. Two patients who maintained their
response (partial response) died of infectious complica-
tions without any evidence of myelosuppression (#14, 30).
Another patient with a partial response (#20) dropped out
because her primary disease relapsed. The other patient
(#3) died of complications from a fall, a death not related
to treatment or chronic GVHD (Table 2). Considering
these infectious complications or relapses during the
study, we performed competing risk analysis for response
to estimate the cumulative incidence rates. The cumula-
tive incidence rate of response was 89.2% at 254 days
while that of events including infection-related death and
relapse was 10.8% at 254 days.
Quality of life 
We assessed the QOL at three designated points (at
baseline and on days 56 and 365). With a score of 50
assumed to represent that of a normal healthy person, the
baseline scores in all domains were below 50 at study
entry in both the ITT and PP analyses (Figure 2). However,
patients reported increased scores in six domains (role
physical, bodily pain, general health perception, role emo-
tional and general mental health), although the changes
were statistically significant only for the role physical and
bodily pain domains (Figure 2A, P<0.05). This finding
became more prominent in the PP analysis, which includ-
S.J. Kim et al.
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Table 1. Baseline characteristics of the patients with chronic GVHD. 
Characteristic                                                               Number        %
                                                                                     (n = 37)          
Demographic
Age (years)                          £ 15                                                     8               21.6
Median 29 (range, 8-57)> 15                                                   29              78.4
Sex                                        Male                                                   20              54.1
                                                   Female                                              17              45.9
Performance status          ECOG 0/1                                          25              67.6
                                                   ECOG 2/3                                          12              32.4
Primary disorder               Acute myeloid leukemia               17              45.9
                                                   Acute lymphoblastic leukemia     8               21.6
                                                   Multiple myeloma                           4               10.8
                                                   Chronic myeloid leukemia            3                8.1
                                                   Myelodysplastic syndrome           2                5.4
                                                   Aplastic anemia                                1                2.7
                                                   Others                                                2                5.4
Combined disorder          Diabetes mellitus                            7               18.9
                                                   Past history of tuberculosis         4               10.8
                                                   Past history of toxic hepatitis      1                2.7
                                                   None                                                  25              67.6
Stem cell transplantation                                                                       
Conditioning regimen       Myeloablative                                  29              78.4
                                                   Reduced intensity                           8               21.6
Stem cell donors                HLA-matched sibling                     16              43.3
                                                   HLA-matched unrelated               17              45.9
                                                   HLA-incomplete matched             4               10.8
                                                   unrelated
Stem cell source                Peripheral blood stem cells         8               21.6
                                                   Bone marrow                                  27              73.0
                                                   Cord blood                                        2                5.4
ABO matching                      Matched                                            15              40.5
                                                   Mismatched                                     22              59.5
Sex matching                       Complete                                          13              35.1
                                                   From male (D) to female (R)    15              40.5
                                                   From female (D) to male (R)     9               24.3
Chronic GVHD
Duration of disease           < 6 months                                      27              73.0
Median 5.2 months         ≥ 6 months                                      10              27.0
(range, 2.2-25.5)
Previous acute GVHD       Absence                                            16              43.2
                                                   Presence                                          21              56.8
Previous CMV                    Absence                                            24              64.9
antigenemia                        Presence                                          13              35.1
Involved organs*               Oral cavity                                        28              75.7
                                                   Skin                                                    22              59.5
                                                   Eyes                                                   21              56.8
                                                   Lung                                                   10              27.0
                                                   Liver                                                    9               24.3
                                                   Musculoskeletal system                7               18.9
                                                   Gut                                                      3                8.1
                                                   Others                                                3                8.1
Immunosuppression       Steroid alone                                    6               16.2
at enrollment                     Steroid + cyclosporine                 11              29.7
                                                   Steroid + tacrolimus                     10              27.0
                                                  Steroid + calcineurin                   10              27.0
                                                   inhibitor and/or others
ECOG: Eastern Cooperative Oncology Group; D: donor; R: recipient; CMV: cytomegalovirus;
*Median number of involved organs per person: 2.78 (range, 1-5).
ed only patients with complete follow-up through to day
365 (Figure 2B). Because all of these patients showed an
objective response, their final score at day 365 approached
50 in several domains, although these changes were not
significant. However, scores in some domains, especially
the physical domains, including physical functioning, role
physical and bodily pain, decreased. Thus, the physical
component summary score decreased as the study pro-
gressed, while the mental component summary score did
not (Figure 2).  
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Table 2. Summary of treatment outcomes in the 37 patients studied.
Baseline characteristic at enrollment Response evaluation (Day) Follow-up
Time after Steroid
N.* Sex/ chronic dosage Immuno- 29 57 85 113 141 169 252 365 Severe adverse Maximum Status after Steroid 
/age GVHD (mg) suppressant events (onset) response enrollment administration
(final dose of steroid)
2 F/19 5.4 40 NR PR PR PR CR CR CR CR CR Alive  Stop
11 M/40 24.0 30 F 1mg, M 250mg CR CR CR CR CR CR CR CR CR Alive Reduction (7.5mg)
17 M/8 13.6 50 PR CR CR CR CR CR CR CR CR Alive Stop
37 F/44 2.4 30 PR PR PR PR CR CR CR CR CR Alive Stop
7 M/26 12.1 20 F 1mg, M 250mg CR CR CR CR CR PR PR PR CR Alive Reduction (5mg)
12 F/52 6.3 30 F 2mg, M 250mg CR CR CR CR CR PR PR PR CR Alive Reduction (10mg)
16 F/15 13.6 50 C 250mg PR CR CR CR CR PR PR PR CR Alive Reduction (10mg)
25 F/29 2.3 50 PR CR CR CR CR CR CR PR CR Alive Reduction (20mg)
1 M/45 26.4 30 C 125mg PR PR PR PR PR PR PR PR PR Alive Reduction (20mg)
5 F/11 2.2 30 F 2mg PR PR PR PR PR PR PR PR PR Alive Reduction (10mg)
8 F/17 6.0 40 F 2mg PR PR PR PR PR PR PR PR PR Alive Reduction (10mg)
19 M/9 25.9 27 F 1mg PR PR PR PR PR PR PR PR PR Alive Reduction (5mg)
26 F/51 12.3 30 C 50mg PR PR PR PR PR PR PR PR PR Alive Reduction (5mg)
27 F/44 37.5 30 C 200mg, A 100mg PR PR PR PR PR PR PR PR PR Alive Stop
28 M/41 4.5 40 A 100mg PR PR PR PR PR PR PR PR PR Alive Reduction (5mg)
31 F/34 23.0 80 C 250mg PR PR PR PR PR PR PR PR PR Alive Stop
33 M/49 2.3 30 F 2mg PR PR PR PR PR PR PR PR PR Alive Reduction (7.5mg)
34 F/15 2.4 30 C 200mg PR PR PR PR PR PR PR PR PR Alive Stop
22 M/8** 33.3 18 C 100mg NR NR NR PR PR PR PR PR PR Alive Reduction (18mg)
23 F/11 8.8 25 C 100mg NR NR NR NR NR NR PR PR PR Alive Reduction (10mg)
35 M/19 4.2 30 NR NR NR NR NR NR PR PR PR Alive Reduction (5mg)
3 M/47 23.8 30 PR PR PR PR PR PR Fall (D205) PR Died at 6.8 months
4 M/16 4.2 20 F 4mg PR PR PR PR Sepsis (D115) PR Died at 4.8 months
20 F/45 3.1 30 F 2mg PR PR PR PR PR PR Primary disease PR Dropped out
relapse (D173)
30 M/8 2.9 10 F 1mg, M 150mg PR PR PR PR PR PR Pneumonia (D169) PR Died at 7.7 months
14 M/17 10.9 30 F 2mg PR PR Pneumonia (D57) PR Died at 3.1 months
36 F/24 3.4 60 C 150mg, Ms 750mg PR PR PD Pulmonary PR Died at 3.5 months
hemorrhage (D106)
10 F/25 9.4 30 C 150mg NR PR PR PR PR PR PD PD PR Alive at 16.6 months
6 M/51 3.5 30 C 200mg PR PR PR PR PD PD Sepsis (D203) PR Died at 6.9 months
13 M/27** 2.2 85 F 2mg PR PD PD PR Dropped out
15 M/18 2.4 80 F 6mg PR PR PD PD PR Dropped out
9 M/52 4.6 30 C 100mg NR PR PR PR PD PD Pneumonia (D169) PR Died at 6.2 months
24 F/38 6.7 24 F 3mg, Ms 720mg NR NR NR Pneumonia (D83) NR Died at 3 months
18 M/35 2.2 40 C 250mg, M 150mg NR NR NR NR Dropped out
21 M/57 37.2 32 C 600mg NR NR Pneumonia (D57) NR Died at 2.1 months
29 M/40 2.3 85 C 200mg, Ms 720mg NR R/O Tuberculosis (D29) NR Dropped out
32 F/43 17.0 30 F 3mg NR R/O Colitis (D33) NR Dropped out
The patients are listed in the order of their maximum response. F: tacrolimus; M: mycophenolate mofetil; C: cyclosporine; A: azathiopurine; Ms: mycophenolate sodium; D: day. * This number
represents the order of registration. ** These two patients received second allogeneic stem cell transplants. NR: no response; PR: partial response; CR: complete response; PD: progressive
disease.
Serum B-cell-activating factor of the tumor necrosis
factor family and immune globulins
The median baseline level of serum BAFF was 1225
pg/mL (range, 129-8188pg/mL), higher than the median
reported for normal healthy Asian people (range 780-861
pg/mL).24,25 Generally, we found that patients with a serum
BAFF lower than 1000 pg/mL had better outcomes. Thus,
78.5% (11/14) of those with lower levels maintained their
response at day 365, while 50% (9/18) of those with high-
er levels had progressive disease or complications,
although this effect was not statistically significant
(P=0.147). Serum BAFF increased continuously, with an
inverse correlation to the sustained treatment-related
decrease in immune globulins (Figure 3). The mean levels
of immune globulins decreased from baseline to 1 year as
follows: IgG, from 773.6 to 528.2 mg/mL (normal range,
700-1600); IgA, from 105.8 to 63.9 mg/mL (normal range,
70-400); and IgM, from 106.2 to 40.2 mg/mL (normal
range, 40-230).
Discussion
Chronic GVHD has increased with the use of unrelated
or HLA-mismatched donors and peripheral blood stem
cells for allogeneic stem cell transplantation.26,27 The most
commonly used treatment for chronic GVHD is systemic
steroid administration; however, many patients are either
steroid-refractory or have a steroid-dependent response.
Thus, chronic GVHD may require long-term use of
steroids and other immunosuppressive agents, although
this treatment is still not satisfactory. Rituximab emerged
as a treatment for chronic GVHD when a patient who had
discontinued steroids incidentally showed improvement
during treatment with rituximab for immune thrombocy-
topenia.15 Results of subsequent studies supported the
effectiveness of rituximab in steroid-refractory chronic
GVHD.12-14,16-19 Four of these studies were prospective and
the overall response rate ranged from 43% to 83%.16-19
However, three pilot studies evaluated only three to seven
patients.16,17,19 One study alone was designed as a phase I/II
study;18 in that study of 21 patients the overall response
rate was greater than 70% and two patients achieved a
complete response at 1 year. However, the study did not
use the criteria for diagnosis of chronic GVHD and
response in clinical trials recommended by the NIH
Consensus Development Project.20,21
Our study is currently the largest one to evaluate the
response of steroid-refractory chronic GVHD to rituximab
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Table 3. Rituximab responses according to manifestation or organ
involved.
Involved Total Complete Partial No Overall 
organ  or number response response response response
manifestation (n) (n) (n) rate *(%)
Skin 22 5 12 5 77.3
Oral cavity 28 4 16 8 71.4
Musculoskeletal 7 0 7 0 100.0
system
Eye 21 0 9 12 42.9
Liver 9 0 4 5 44.4
Gut 3 0 1 2 33.3
Lung 11 0 1 10 9.1
Hemolytic anemia 2 2 0 0 100.0
Proteinuria 1 1 0 0 100.0
*Overall response includes complete and partial responses.
Figure 2. (A) In the ITT analysis of
quality of life, patients reported
increased scores in six domains (RP,
BP, GH, SF, RE and MH) although only
the effects on RP and BP were statis-
tically significant (P<0.05). (B) PP
analysis, including only patients with
complete follow-up through day 365
showed a tendency toward improve-
ment in all domains of the SF36
quality of life questionnaire although
not statistically significant. GH, gen-
eral health perceptions;  PF, physical
function; MH, general mental health;
RP, role function limitation due to
physical problems; RE, role function
limitation due to emotional prob-
lems; BP, bodily pain; VT, vitality; SF,
social function; PCS, physical compo-
nent summary; MCS,  mental compo-
nent summary
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using the NIH criteria. Unlike previous prospective studies
which recruited only adults, our group of 37 patients
included eight patients who were 15 years old or younger.
The previous studies used a uniform treatment schedule
consisting of a weekly rituximab infusion for 4 weeks,
with an additional 4 weeks of this treatment for patients
with no response or incomplete response at the first eval-
uation.16,18 We treated our group initially with the same
schedule, and at the end of an induction phase (day 29),
observed an objective response in 26 patients (70.3%,
26/37). After that, we proceeded to the monthly adminis-
tration of rituximab for 4 months as a maintenance treat-
ment. During or after this phase, six patients who did not
respond to the weekly rituximab showed a delayed
response (Table 2). Thus, the objective response rate based
on the maximum response of each patient was 86.5%
(32/37, Table 2). However, only 22 patients completed the
study as planned; 15 patients dropped out when their dis-
ease progressed or when they developed an infection. The
final overall response rate at 1 year was, therefore, 56.8%
(21/37), and these patients were able to discontinue
steroids or reduce their dosage (Table 2). When infection-
related deaths and relapses were considered as competing
risks, the cumulative incidence rate of response was
89.2% at 254 days. 
The musculoskeletal and dermal manifestations of
GVHD responded better than did manifestations in the
eyes, liver and gut (Table 3), consistent with results of pre-
vious studies.13,14,17,18 In our study, however, oral cavity
lesions showed better responses than those previously
reported.11 This may reflect the shorter duration of chronic
GVHD in our study (median, 5.2 months) than in the pre-
vious ones (medians, 14-37 months), because long-stand-
ing disease might result in destruction of target tissues
such as the salivary glands.14,16,18 As in previous studies, the
lungs showed the least responsiveness, while immune-
mediated manifestations such as hemolytic anemia
responded well to rituximab. Although we found no clin-
ical parameters that predicted the response to rituximab,
patients 15 years old or younger responded better than
those over 15 years old; seven young patients maintained
their response until their last visit (7/8, 87.5%) while 14
older patients maintained their response through to the
end of the planned study period (14/29, 48.3%). 
In a recent review of QOL assessments, the majority of
studies suggested that more than 60% of patients reported
good to excellent QOL in the 1 to 4 years after allogeneic
stem cell transplantation.28 All of our patients, however,
showed scores below the average for normal healthy peo-
ple in all domains of the baseline QOL evaluation.
Moreover, despite clinical improvement in the majority of
patients after treatment, the QOL did not increase signifi-
cantly, although it showed a positive trend (Figure 2). This
finding suggests that steroid-refractory chronic GVHD
may seriously impair QOL, even after the resolution of
symptoms. Active behavioral interventions as well as
medical treatments may be required to improve and main-
tain QOL. 
Although we observed a delayed response during or
after the maintenance phase, disease progression also
occurred in this later time. Moreover, eight patients died
of infectious complications, including pneumonia and sep-
sis (Table 2). Because all of these patients received both
steroids and other immunosuppressive agents throughout
the study, we could not demonstrate a causal relationship
between rituximab and infection. However, serum
immunoglobulin levels remained suppressed below the
normal range until the final visit (day 365, Figure 3), which
may have increased susceptibility to infection. While our
monthly rituximab regimen may have helped responders
to maintain their response, it may also have resulted in a
higher rate of infectious complications than those reported
in previous rituximab trials. Because most of the infections
occurred during the maintenance phase and our treatment
protocol did not include the prophylactic administration
of immunoglobulin, our high incidence of infectious com-
plications might be related to our maintenance rituximab
infusion-associated prolonged B-cell depletion. Thus, the
patients should have received prophylactic immunoglobu-
lin and careful monitoring for infection. A recent study
found a positive effect of low-dose rituximab (50 mg/m2)
on steroid-refractory chronic GVHD,29 which suggests
that dosage reduction may sustain response without
increasing the risk of infection. 
In our study, patients with a serum BAFF higher than
1000 pg/mL showed treatment failure (e.g. disease progres-
sion) more frequently than did those with lower levels.
Although this effect was not statistically significant
(P=0.147), it is consistent with a role of BAFF in the occur-
rence and severity of chronic GVHD.9,10 However, serum
BAFF increased during the study period, with an inverse
correlation to the decrease in immune globulins (Figure 3).
Rituximab for steroid-refractory chronic GVHD
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Figure 3. Serial changes in serum BAFF and immuno -
globulins. Serum BAFF increased continuously, but
was inversely correlated with the sustained decrease
in immune globulins.  
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This decrease in immune globulins and increase in the
level of serum BAFF may be related to the depletion of B
cells, because rituximab can deplete normal B cells. The
serum level of BAFF during treatment may, therefore, not
be of any additional value for predicting the response or
activity of chronic GVHD although a pre-treatment level
of BAFF lower than 1000 pg/mL seemed to be associated
with the likelihood of response to rituximab. However,
this association of pre-treatment level of serum BAFF
with the response to rituximab was not statistically sig-
nificant and might be related to the number of patients in
our study. Thus, it may be worth extending the study to
include more patients to confirm the association of serum
BAFF with treatment response and disease activity of
chronic GVHD.
In summary, we report here the largest multicenter
study to date evaluating the efficacy of rituximab using
the NIH criteria for diagnosis and response measurement
for clinical trials in steroid-refractory chronic GVHD.20,21
We found that rituximab may reduce clinical manifesta-
tions, permit steroid discontinuation, and improve QOL in
patients with this disease. However, patients may require
prophylactic treatment for infections related to B-cell
depletion. 
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